从2027年1月1日起, Novo Nordisk 将美国对Ozempic和Wegovy的价格削减50%, 以提高可负担性。 Novo Nordisk cuts U.S. prices for Ozempic and Wegovy by up to 50% starting Jan. 1, 2027, to boost affordability.

从2027年1月1日起 Novo Nordisk将减少美国, Ozempic 和 Wegovy 的名单价格将下降50%, Novo Nordisk is going to reduce U.S. Beginning January 1, 2027, list prices for Ozempic and Wegovy will be reduced by up to 50%, with the monthly price set at $675. 这表示Ozempic减少35%,Wegovy减少50%。 This represents a 35% decrease for Ozempic and a 50% reduction for Wegovy. Wegovy和Rybelsus的药片形式也将减少价格。 Wegovy and Rybelsus pill forms will also see price reductions. 这一行动反映了GLP-1药物市场竞争和定价压力的加剧,与降低的医疗保健价格是一致的。 The action reflects increased competition and pricing pressure in the GLP-1 drug market and is consistent with lower Medicare prices. 鉴于现金支付保健模式的趋势,该公司表示,修改的目的是提高付款人和病人的可负担性。 In light of the trend toward cash-pay healthcare models, the company stated that the modifications are intended to increase affordability for both payers and patients.